These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32388692)

  • 1. Real-world effectiveness and safety of tolvaptan in liver cirrhosis patients with hepatic edema: results from a post-marketing surveillance study (START study).
    Sakaida I; Terai S; Kurosaki M; Okada M; Hirano T; Fukuta Y
    J Gastroenterol; 2020 Aug; 55(8):800-810. PubMed ID: 32388692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of factors predicting the response to tolvaptan in patients with liver cirrhosis and hepatic edema.
    Atsukawa M; Tsubota A; Kato K; Abe H; Shimada N; Asano T; Ikegami T; Koeda M; Okubo T; Arai T; Nakagawa-Iwashita A; Yoshida Y; Hayama K; Itokawa N; Kondo C; Chuganji Y; Matsuzaki Y; Iwakiri K
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1256-1263. PubMed ID: 29215154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of tolvaptan in liver cirrhosis patients with edema: Interim results of post-marketing surveillance of tolvaptan in liver cirrhosis (START study).
    Sakaida I; Terai S; Kurosaki M; Yasuda M; Okada M; Bando K; Fukuta Y
    Hepatol Res; 2017 Oct; 47(11):1137-1146. PubMed ID: 27958663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma concentration and efficacy of tolvaptan in cirrhotic patients with refractory ascites.
    Sagawa E; Okubo H; Ando H; Sorin Y; Kanazawa R; Nakadera E; Fukada H; Kokubu S; Miyazaki A
    J Pharmacol Sci; 2019 Apr; 139(4):373-376. PubMed ID: 30857764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of Tolvaptan in real-world patients with autosomal dominant polycystic kidney disease- interim results of SLOW-PKD surveillance.
    Mochizuki T; Muto S; Miyake M; Tanaka T; Wang W
    Clin Exp Nephrol; 2021 Nov; 25(11):1231-1239. PubMed ID: 34228250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan for the treatment of liver cirrhosis oedema.
    Sakaida I
    Expert Rev Gastroenterol Hepatol; 2014 Jul; 8(5):461-70. PubMed ID: 24678622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term administration of Tolvaptan to patients with decompensated cirrhosis.
    Kanayama K; Chiba T; Kobayashi K; Koroki K; Maruta S; Kanzaki H; Kusakabe Y; Saito T; Kiyono S; Nakamura M; Ogasawara S; Suzuki E; Ooka Y; Nakamoto S; Yasui S; Kanda T; Maruyama H; Kato J; Kato N
    Int J Med Sci; 2020; 17(7):874-880. PubMed ID: 32308540
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG
    World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.
    Sakaida I; Terai S; Nakajima K; Shibasaki Y; Tachikawa S; Tsubouchi H
    J Gastroenterol; 2017 Feb; 52(2):229-236. PubMed ID: 27379386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis.
    Okita K; Sakaida I; Okada M; Kaneko A; Chayama K; Kato M; Sata M; Yoshihara H; Ono N; Murawaki Y
    J Gastroenterol; 2010 Sep; 45(9):979-87. PubMed ID: 20387081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
    Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
    Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema.
    Atsukawa M; Tsubota A; Takaguchi K; Toyoda H; Iwasa M; Ikegami T; Chuma M; Nozaki A; Uojima H; Hiraoka A; Fukunishi S; Yokohama K; Tada T; Kato K; Abe H; Tani J; Okubo H; Watanabe T; Hattori N; Tsutsui A; Senoh T; Yoshida Y; Okubo T; Itokawa N; Nakagawa-Iwashita A; Kondo C; Arai T; Michitaka K; Iio E; Kumada T; Tanaka Y; Takei Y; Iwakiri K
    J Gastroenterol Hepatol; 2020 Jul; 35(7):1229-1237. PubMed ID: 31881554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response criteria of tolvaptan for the treatment of hepatic edema.
    Hiramine Y; Uojima H; Nakanishi H; Hiramatsu A; Iwamoto T; Kimura M; Kawaratani H; Terai S; Yoshiji H; Uto H; Sakaida I; Izumi N; Okita K; Koike K
    J Gastroenterol; 2018 Feb; 53(2):258-268. PubMed ID: 28664229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema.
    Sakaida I; Yamashita S; Kobayashi T; Komatsu M; Sakai T; Komorizono Y; Okada M; Okita K;
    J Int Med Res; 2013 Jun; 41(3):835-47. PubMed ID: 23685892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients.
    Nakagawa A; Atsukawa M; Tsubota A; Kondo C; Okubo T; Arai T; Itokawa N; Narahara Y; Iwakiri K
    World J Gastroenterol; 2016 Jun; 22(21):5104-13. PubMed ID: 27275103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Effectiveness and Tolerability of Tolvaptan in Patients With Heart Failure　- Final Results of the Samsca Post-Marketing Surveillance in Heart Failure (SMILE) Study.
    Kinugawa K; Sato N; Inomata T; Yasuda M; Shimakawa T; Fukuta Y
    Circ J; 2019 Jun; 83(7):1520-1527. PubMed ID: 31118355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of tolvaptan non-responders and outcomes of tolvaptan treatment of ascites.
    Iwamoto T; Maeda M; Saeki I; Hidaka I; Tajima K; Ishikawa T; Takami T; Sakaida I
    J Gastroenterol Hepatol; 2019 Jul; 34(7):1231-1235. PubMed ID: 30370940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Tajiri K; Tokimitsu Y; Ito H; Atarashi Y; Kawai K; Minemura M; Yasumura S; Takahara T; Shimizu Y; Sugiyama T
    Dig Dis; 2018; 36(4):314-321. PubMed ID: 29852495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical implications with tolvaptan on monitored bioimpedance-defined fluid status in patients with cirrhotic ascites: an observational study.
    Shiba S; Chu PS; Nakamoto N; Yamataka K; Taniki N; Ojiro K; Yamaguchi A; Morikawa R; Yoshida A; Ikura A; Ebinuma H; Saito H; Kanai T
    BMC Gastroenterol; 2020 Mar; 20(1):53. PubMed ID: 32138675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis.
    Namba M; Hiramatsu A; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Kawaoka T; Tsuge M; Imamura M; Chayama K
    J Gastroenterol; 2020 Feb; 55(2):217-226. PubMed ID: 31485782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.